SHANGHAI OPM BIOSCIENCES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.78 CNY | +1.88% |
|
-2.05% | -33.33% |
| May. 09 | OPM Biosciences' Shareholder to Cut Stake | MT |
| Apr. 29 | Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 8,460 | 6,332 | 4,221 | - | - |
| Enterprise Value (EV) 1 | 8,460 | 6,332 | 4,221 | 4,221 | 4,221 |
| P/E ratio | 47.9 x | 117 x | 47.4 x | 27.5 x | 19.2 x |
| Yield | - | 0.42% | 0.9% | 2.01% | 3.97% |
| Capitalization / Revenue | - | 26 x | 12.4 x | 8.6 x | 6.33 x |
| EV / Revenue | - | 26 x | 12.4 x | 8.6 x | 6.33 x |
| EV / EBITDA | - | 66.2 x | 27.7 x | 17.5 x | 13.7 x |
| EV / FCF | - | -323 x | 101 x | -1,407 x | 64 x |
| FCF Yield | - | -0.31% | 0.99% | -0.07% | 1.56% |
| Price to Book | - | 2.93 x | 1.91 x | 1.82 x | 1.79 x |
| Nbr of stocks (in thousands) | 114,772 | 114,772 | 114,772 | - | - |
| Reference price 2 | 73.71 | 55.17 | 36.78 | 36.78 | 36.78 |
| Announcement Date | 2/23/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 243.1 | 339.5 | 491 | 667 |
| EBITDA 1 | - | 95.71 | 152.5 | 241.5 | 308 |
| EBIT 1 | - | 61.81 | 99.33 | 173 | 251.5 |
| Operating Margin | - | 25.42% | 29.26% | 35.23% | 37.7% |
| Earnings before Tax (EBT) 1 | - | 61.67 | 101.3 | 174.7 | 252.5 |
| Net income 1 | 105.4 | 54.04 | 88.73 | 153.6 | 219.6 |
| Net margin | - | 22.23% | 26.14% | 31.28% | 32.92% |
| EPS 2 | 1.540 | 0.4700 | 0.7767 | 1.337 | 1.915 |
| Free Cash Flow 1 | - | -19.59 | 42 | -3 | 66 |
| FCF margin | - | -8.06% | 12.37% | -0.61% | 9.89% |
| FCF Conversion (EBITDA) | - | - | 27.54% | - | 21.43% |
| FCF Conversion (Net income) | - | - | 47.33% | - | 30.05% |
| Dividend per Share 2 | - | 0.2300 | 0.3300 | 0.7400 | 1.460 |
| Announcement Date | 2/23/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -19.6 | 42 | -3 | 66 |
| ROE (net income / shareholders' equity) | - | 2.48% | 4.13% | 6.57% | 9.35% |
| ROA (Net income/ Total Assets) | - | - | 4.2% | 6.6% | - |
| Assets 1 | - | - | 2,113 | 2,327 | - |
| Book Value Per Share 2 | - | 18.80 | 19.30 | 20.20 | 20.50 |
| Cash Flow per Share 2 | - | 0.5000 | 0.4400 | 1.950 | - |
| Capex 1 | - | 77.5 | 88 | 90 | 67.5 |
| Capex / Sales | - | 31.9% | 25.92% | 18.33% | 10.12% |
| Announcement Date | 2/23/23 | 2/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
36.78
CNY
Average target price
58.66
CNY
Spread / Average Target
+59.49%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 585M | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- 688293 Stock
- Financials Shanghai OPM Biosciences Co., Ltd.
